Sleep Trial to Prevent Alzheimer's Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Alzheimer Disease
- Sleep
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 65 years and 125 years
- Gender
- Both males and females
Description
This study will investigate if long-term treatment with suvorexant will slow amyloid-? accumulation in the brain. Amyloid-? is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected on brain sc...
This study will investigate if long-term treatment with suvorexant will slow amyloid-? accumulation in the brain. Amyloid-? is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected on brain scans (primary outcome).
Tracking Information
- NCT #
- NCT04629547
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Brendan Lucey, MD Washington Univeristy School of Medicine
Get Well Soon